BENLYSTA 200 mg/mL
belimumab · SOLUTION · GlaxoSmithKline LLC
No Recall History
Plain English
BENLYSTA is a solution containing belimumab at 200 mg/mL, taken subcutaneous. Manufactured by GlaxoSmithKline LLC.
Key Facts
- Brand Name
- BENLYSTA
- Generic Name
- belimumab
- NDC Code (Product)
49401-088- Manufacturer
- GlaxoSmithKline LLC
- Strength
- 200 mg/mL
- Dosage Form
- SOLUTION
- Route
- SUBCUTANEOUS
- Marketing Status
- Application #
- BLA761043
- Drug Class
- B Lymphocyte Stimulator-specific Inhibitor [EPC]
- Marketing Start
- 07/20/2017
Recall History
No Recall HistoryFrequently Asked Questions
What is BENLYSTA used for?
BENLYSTA contains belimumab. It is a solution taken subcutaneous. Consult your doctor for specific uses.
Is BENLYSTA a controlled substance?
BENLYSTA is not classified as a controlled substance by the DEA.
What is the generic name for BENLYSTA?
The generic name for BENLYSTA is belimumab. There are no other listed brand versions of belimumab.
What is the NDC code for BENLYSTA 200 mg/mL?
The NDC (National Drug Code) for BENLYSTA 200 mg/mL is 49401-088, listed by GlaxoSmithKline LLC.
Other BENLYSTA Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)